New Data Brings Yescarta Closer To Blockbuster Territory

Potential Market Adds 14,000 US Patients

 
• By Alaric DeArment
3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration
Gilead's Kite division announced topline results from the ZUMA-7 trial of Yescarta in second-line LBCL. • Source: Shutterstock

More from Immuno-oncology

More from Anticancer